Endogenous bioactive peptides as potential biomarkers for atherosclerotic coronary heart disease

Sensors

Volumn 12, Issue 4, 2012, Pages 4974-4985

  Watanabe, Takuya ^a   Sato, Kengo ^a   Itoh, Fumiko ^a   Wakabayashi, Kohei ^b   Shichiri, Masayoshi ^c   Hirano, Tsutomu ^d  

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^b SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

^c KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Acyl coenzyme a: cholesterol acyltransferase 1; Adiponectin; Atherosclerosis; Biomarker; Coronary artery disease; Glucagon like peptide 1; Heregulin 1; Macrophage; Salusin

Indexed keywords

BIOLOGICAL MARKER; PEPTIDE;

ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; HUMAN; METABOLISM; REVIEW;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CORONARY DISEASE; HUMANS; PEPTIDES;

EID: 84860133799     PISSN: 14248220     EISSN: None     Source Type: Journal    
DOI: 10.3390/s120404974     Document Type: Review

References (72)

1. Hochholzer, W.; Morrow, D.A.; Giugliano, R.P. Novel biomarkers in cardiovascular disease: Update 2010. Am. J. Cardiol. 2010, 160, 583-594.
2. Zakynthinos, E.; Pappa, N. Inflammatory biomarkers in coronary artery disease. J. Cardiol. 2009, 53, 317-333.
3. Corrado, E.; Rizzo, M.; Coppola, G.; Fattouch, K.; Novo, G.; Marturana, I.; Ferrara, F.; Novo, S. An update on the role of markers of inflammation in atherosclerosis. J. Atheroscler. Thromb. 2010, 17, 1-11.
4. Nagesh, C.M.; Roy, A. Role of biomarkers in risk stratification of acute coronary syndrome. Indian J. Med. Res. 2010, 132, 627-633.
5. Tsimikas, S. Oxidative biomarkers in the diagnosis and prognosis of cardiovascular disease. Am. J. Cardiol. 2006, 98(Suppl.), 9-17.
6. Watanabe, T.; Koba, S. Roles of serotonin in atherothrombosis and related diseases. Atherothrombosis 2012, in press.
7. Watanabe, T.; Arita, S.; Shiraishi, Y.; Suguro, T.; Sakai, T.; Hongo, S.; Miyazaki, A. Human urotensin II promotes hypertension and atherosclerotic cardiovascular diseases. Curr. Med. Chem. 2009, 16, 550-563.
8. Watanabe, T.; Sato, K.; Itoh, F.; Iso, Y.; Nagashima, M.; Hirano, T.; Shichiri, M. The roles of salusins in atherosclerosis and related cardiovascular diseases. J. Am. Soc. Hypertens. 2011, 5, 359-365.
9. Watanabe, T.; Sato, K.; Itoh, F.; Iso, Y. Pathogenic involvement of heregulin-β1 in anti-atherogenesis. Regul. Pept. 2012, 175, 11-14.
10. Barseghian, A.; Gawande, D.; Bajaj, M. Adiponectin and vulnerable atherosclerotic plaques. J. Am. Coll. Cardiol. 2011, 57, 761-770.
11. Nagashima, M.; Watanabe, T.; Terasaki, M.; Tomoyasu, M.; Nohtomi, K.; Kim-Kaneyama, J.; Miyazaki, A.; Hirano, T. Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice. Diabetologia 2011, 54, 2649-2659.
12. Allahverdian, S.; Pannu, P.S.; Francis, G.A. Contribution of monocyte-derived macrophages and smooth muscle cells to arterial foam cell formation. Cardiovasc. Res. 2012, in press.
13. Drucker, D.J. The biology of incretin hormones. Cell Metab. 2006, 3, 153-165.
14. Shichiri, M.; Ishimaru, S.; Ota, T.; Nishikawa, T.; Isogai, T.; Hirata, Y. Salusins: Newly identified bioactive peptides with hemodynamic and mitogenic activities. Nat. Med. 2003, 9, 1166-1172.
15. Chinetti, G.; Zawadski, C.; Fruchart, J.C.; Staels, B. Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARα, PPARγ, and LXR. Biochem. Biophys. Res. Commun. 2004, 314, 151-158.
16. Xu, G.; Watanabe, T.; Iso, Y.; Koba, S.; Sakai, T.; Nagashima, M.; Arita, S.; Hongo, S.; Ota, H.; Kobayashi, Y. et al. Preventive effects of heregulin-β1 on macrophage foam cell formation and atherosclerosis. Circ. Res. 2009, 105, 500-510.
17. Russell, K.S.; Stern, D.F.; Polverini, P.J.; Bender, J.R. Neuregulin activation of ErbB receptors in vascular endothelium leads to angiogenesis. Am. J. Physiol. 1999, 277, H2205-H2211.
18. Arakawa, M.; Mita, T.; Azuma, K.; Ebato, C.; Goto, H.; Nomiyama, T.; Fujitani, Y.; Hirose, T.; Kawamori, R.; Watada, H. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010, 59, 1030-1037.
19. Ding, M.; Xie, Y.; Wagner, R.J.; Jin, Y.; Carrao, A.C.; Liu, L.S.; Guzman, A.K.; Powell, R.J.; Hwa, J.; Rzucidlo, E.M. et al. Adiponectin induces vascular smooth muscle cell differentiation via repression of mammalian target of rapamycin complex 1 and FoxO4. Arterioscler. Thromb. Vasc. Biol. 2011, 31, 1403-1410.
20. Clement, C.M.; Thomas, L.K.; Mou, Y.; Croslan, D.R.; Gibbons, G.H.; Ford, B.D. Neuregulin-1 attenuates neointimal formation following vascular injury and inhibits the proliferation of vascular smooth muscle cells. J. Vasc. Res. 2007, 44, 303-312.
21. Ding, G.; Qin, Q.; He, N.; Francis-David, S.C.; Hou, J.; Liu, J.; Ricks, E.; Yang, Q. Adiponectin and its receptors are expressed in adult ventricular cardiomyocytes and upregulated by activation of peroxisome proliferator-activated receptor γ. J. Mol. Cell. Cardiol. 2007, 43, 73-84.
22. Iwamoto, R.; Yamazaki, S.; Asakura, M.; Takashima, S.; Hasuwa, H.; Miyado, K.; Adachi, S.; Kitakaze, M.; Hashimoto, K.; Raab, G. et al. Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function. Proc. Natl. Acad. Sci. USA 2003, 100, 3221-3226.
23. Artinian, S.B.; Al Lafi, S.M.; Boutary, S.S.; Bitar, K.M.; Zwainy, N.S.; Bikhazi, A.B. Assessment of glucagon-like peptide-1 analogue and renin inhibitor on the binding and regulation of GLP-1 receptor in type 1 diabetic rat hearts. Exp. Diabetes Res. 2011, 2011, 489708.
24. Arita, Y.; Kihara, S.; Ouchi, N.; Maeda, K.; Kuriyama, H.; Okamoto, Y.; Kumada, M.; Hotta, K.; Nishida, M.; Takahashi, M. et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor induced common postreceptor signal in vascular smooth muscle cell. Circulation 2002, 105, 2893-2898.
25. Ouchi, N.; Walsh, K. Adiponectin as an anti-inflammatory factor. Clinica. Chimica. Acta 2007, 380, 24-30.
26. Xu, Z.; Ford, G.D.; Croslan, D.R.; Jiang, J.; Gates, A.; Allen, R.; Ford, B.D. Neuroprotection by neuregulin-1 following focal stroke is associated with the attenuation of ischemia-induced pro-inflammatory and stress gene expression. Neurobiol. Dis. 2005, 19, 461-470.
27. Motoshima, H.; Wu, X.; Mahadev, K.; Goldstein, B.J. Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochem. Biophys. Res. Commun. 2004, 315, 264-271.
28. Timolati, F.; Ott, D.; Pentassuglia, L.; Giraud, M.N.; Perriard, J.C.; Suter, T.M.; Zuppinger, C. Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes. J. Mol. Cell. Cardiol. 2006, 41, 845-854.
29. Liu, F.Q.; Zhang, X.L.; Gong, L.; Wang, X.P.; Wang, J.; Hou, X.G.; Sun, Y.; Qin, W.D.; Wei, S.J.; Zhang, Y. et al. Glucagon-like peptide 1 protects microvascular endothelial cells by inactivating the PARP-1/iNOS/NO pathway. Mol. Cell. Endocrinol. 2011, 339, 25-33.
30. Cheng, K.K.; Lam, K.S.; Wang, Y.; Huang, Y.; Carling, D.; Wu, D.; Wong, C.; Xu, A. Adiponectin-induced endothelial nitric oxide synthase activation and nitric oxide production are mediated by APPL1 in endothelial cells. Diabetes 2007, 56, 1387-1394.
31. Brero, A.; Ramella, R.; Fitou, A.; Dati, C.; Alloatti, G.; Gallo, M.P.; Levi, R. Neuregulin-1β1 rapidly modulates nitric oxide synthesis and calcium handling in rat cardiomyocytes. Cardiovasc. Res. 2010, 88, 443-452.
32. Ding, L.; Zhang, J. Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells. Acta Pharmacol. Sin. 2012, 33, 75-81.
33. Shibata, R.; Izumiya, Y.; Sato, K.; Papanicolaou, K.; Kihara, S.; Colucci, W.S.; Sam, F.; Ouchi, N.; Walsh, K. Adiponectin protects against the development of systolic dysfunction following myocardial infarction. J. Mol. Cell. Cardiol. 2007, 42, 1065-1074.
34. Hedhli, N.; Huang, Q.; Kalinowski, A.; Palmeri, M.; Hu, X.; Russell, R.R.; Russell, K.S. Endothelium-derived neuregulin protects the heart against ischemic injury. Circulation 2011, 123, 2254-2262.
35. Nikolaidis, L.A.; Doverspike, A.; Hentosz, T.; Zourelias, L.; Shen, Y.T.; Elahi, D.; Shannon, R.P. Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines. J. Pharmacol. Exp. Ther. 2005, 312, 303-308.
36. Matsuzawa, Y. Adiponectin: A key player in obesity related disorders. Curr. Pharm. Des. 2010, 16, 1896-1901.
37. Yan, X.H.; Li, L.; Pan, Y.X.; Lu, H.; Rong, W.F.; Yan, L.; Ren, A.J.; Tang, C.S.; Yuan, W.J. Salusins protect neonatal rat cardiomyocytes from serum deprivation-induced cell death through upregulation of GRP78. J. Cardiovasc. Pharmacol. 2006, 48, 41-46.
38. Furukawa, K.; Hori, M.; Ouchi, N.; Kihara, S.; Funahashi, T.; Matsuzawa, Y.; Miyazaki, A.; Nakayama, H.; Horiuchi, S. Adiponectin down-regulates acyl-coenzyme A: Cholesterol acyltransferase-1 in cultured human monocyte-derived macrophages. Biochem. Biophys. Res. Commun. 2004, 317, 831-836.
39. Watanabe, T.; Nishio, K.; Kanome, T.; Matsuyama, T.; Koba, S.; Sakai, T.; Sato, K.; Hongo, S.; Nose, K.; Ota, H. et al. Impact of salusin-α and -β on human macrophage foam cell formation and coronary atherosclerosis. Circulation 2008, 117, 638-648.
40. Ouchi, N.; Kihara, S.; Arita, Y.; Nishida, M.; Matsuyama, A.; Okamoto, Y.; Ishigami, M.; Kuriyama, H.; Kishida, K.; Nishizawa, H. et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001, 103, 1057-1063.
41. Tsubakio-Yamamoto, K.; Matsuura, F.; Koseki, M.; Oku, H.; Sandoval, J.C.; Inagaki, M.; Nakatani, K.; Nakaoka, H.; Kawase, R.; Yuasa-Kawase, M. et al. Adiponectin prevents atherosclerosis by increasing cholesterol efflux from macrophages. Biochem. Biophys. Res. Commun. 2008, 375, 390-394.
42. Tian, L.; Luo, N.; Klein, R.L.; Chung, B.H.; Garvey, W.T.; Fu, Y. Adiponectin reduces lipid accumulation in macrophage foam cells. Atherosclerosis 2009, 202, 152-161.
43. Okamoto, Y.; Kihara, S.; Ouchi, N.; Nishida, M.; Arita, Y.; Kumada, M.; Ohashi, K.; Sakai, N.; Shimomura, I.; Kobayashi, H. et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002, 106, 2767-2770.
44. Nagashima, M.; Watanabe, T.; Shiraishi, Y.; Morita, R.; Terasaki, M.; Arita, S.; Hongo, S.; Sato, K.; Shichiri, M.; Miyazaki, A. et al. Chronic infusion of salusin-α and -β exerts opposite effects on atherosclerotic lesion development in apolipoprotein E-deficient mice. Atherosclerosis 2010, 212, 70-77.
45. Luo, N.; Liu, J.; Chung, B.H.; Yang, Q.; Klein, R.L.; Garvey, W.T.; Fu, Y. Macrophage adiponectin expression improves insulin sensitivity and protects against inflammation and atherosclerosis. Diabetes 2010, 59, 791-799.
46. Zhou, Y.; Wei, Y.; Wang, L.; Wang, X.; Du, X.; Sun, Z.; Dong, N.; Chen, X. Decreased adiponectin and increased inflammation expression in epicardial adipose tissue in coronary artery disease. Cardiovasc. Diabetol. 2011, 10, 2.
47. Nakano, Y.; Tajima, S.; Yoshimi, A.; Akiyama, H.; Tsushima, M.; Tanioka, T.; Negoro, T.; Tomita, M.; Tobe, T. A novel enzyme-linked immunosorbent assay specific for high-molecular-weight adiponectin. J. Lipid Res. 2006, 47, 1572-1582.
48. von Eynatten, M.; Humpert, P.M.; Bluemm, A.; Lepper, P.M.; Hamann, A.; Allolio, B; Nawroth, P.P.; Bierhaus, A.; Dugi, K.A. High-molecular weight adiponectin is independently associated with the extent of coronary artery disease in men. Atherosclerosis 2008, 99, 123-128.
49. Liang, K.W.; Sheu, W.H.; Lee, W.L.; Liu, T.J.; Ting, C.T.; Hsieh, Y.C.; Wang, K.Y.; Chen, Y.T.; Lee, W.J. Decreased circulating protective adiponectin level is associated with angiographic coronary disease progression in patients with angina pectoris. Int. J. Cardiol. 2008, 129, 76-80.
50. Broedl, U.C.; Lebherz, C.; Lehrke, M.; Stark, R.; Greif, M.; Becker, A.; von Ziegler, F.; Tittus, J.; Reiser, M.; Becker, C. et al. Low adiponectin levels are an independent predictor of mixed and non-calcified coronary atherosclerotic plaques. PLoS One 2009, 4, e4733.
51. Baldasseroni, S.; Mannucci, E.; Orso, F.; Di Serio, C.; Pratesi, A.; Bartoli, N.; Marella, G.A.; Colombi, C.; Foschini, A.; Valoti, P. et al. Adiponectin in outpatients with coronary artery disease: Independent predictors and relationship with heart failure. Nutr. Metab. Cardiovasc. Dis. 2012, 22, 292-299.
52. Ky, B.; Kimmel, S.E.; Safa, R.N.; Putt, M.E.; Sweitzer, N.K.; Fang, J.C.; Sawyer, D.B.; Cappola, T.P. Neuregulin-1β is associated with disease severity and adverse outcomes in chronic heart failure. Circulation 2009, 120, 310-317.
53. Geisberg, C.A.; Wang, G.; Safa, R.N.; Smith, H.M.; Anderson, B.; Peng, X.Y.; Veerkamp, B.; Zhao, D.X.; Blakemore, D.; Yu, C. et al. Circulating neuregulin-1β levels vary according to the angiographic severity of coronary artery disease and ischemia. Coron. Artery Dis. 2011, 22, 577-582.
54. Sato, K.; Koyama, T.; Tateno, T.; Hirata, Y.; Shichiri, M. Presence of immunoreactive salusin-α in human serum and urine. Peptides 2006, 27, 2561-2566.
55. Watanabe, T.; Suguro, T.; Sato, K.; Koyama, T.; Nagashima, M.; Kodate, S.; Hirano, T.; Adachi, M.; Shichiri, M.; Miyazaki, A. Serum salusin-α levels are decreased and correlated negatively with carotid atherosclerosis in essential hypertensive patients. Hypertens. Res. 2008, 31, 463-468.
56. Kimoto, S.; Sato, K.; Watanabe, T.; Suguro, T.; Koyama, T.; Shichiri, M. Serum levels and urinary excretion of salusin-α in renal insufficiency. Regul. Pept. 2010, 162, 129-132.
57. Ozgen, M.; Koca, S.S.; Dagli, N.; Balin, M.; Ustundag, B.; Isik, A. Serum salusin-alpha level in rheumatoid arthritis. Regul. Pept. 2010, 167, 125-128.
58. Ti, Y.; Wang, F.; Wang, Z.H.; Wang, X.L.; Zhang, W.; Zhang, Y.; Bu, P.L. Associations of serum salusin-α levels with atherosclerosis and left ventricular diastolic dysfunction in essential hypertension. J. Hum. Hypertens. 2012, in press.
59. Simsek, Y.; Celik, O.; Yilmaz, E.; Karaer, A.; Dogan, C.; Aydin, S.; Ozer, A. Serum levels of apelin, salusin-alpha, and salusin-beta in normal pregnancy and preeclampsia. J. Matern. Fetal. Neonatal. Med. 2012, in press.
60. Matsubara, J.; Sugiyama, S.; Sugamura, K.; Nakamura, T.; Fujiwara, Y.; Akiyama, E.; Kurokawa, H.; Nozaki, T.; Ohba, K.; Konishi, M. et al. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. J. Am. Coll. Cardiol. 2012, 59, 265-276
61. Lee, S.; Yabe, D.; Nohtomi, K.; Morita, R.; Seino, Y.; Hirano, T. Intact glucagon-like peptide-1 levels are not decreased in Japanese patients with type 2 diabetes. Endocr. J. 2011, 57, 119-126.
62. Nathanson, D.; Zethelius, B.; Berne, C.; Holst, J.J.; Sjöholm, A.; Nyström, T. Reduced plasma levels of glucagon-like peptide-1 in elderly men are associated with impaired glucose tolerance but not with coronary heart disease. Diabetologia 2010, 53, 277-280.
63. El-Menyar, A.; Rizk, N.; Al Nabti, A.D.; Hassira, S.A.; Singh, R.; Abdel Rahman, M.O.; Suwaidi, J.A. Total and high molecular weight adiponectin in patients with coronary artery disease. J. Cardiovasc. Med. 2009, 10, 310-315.
64. Brodov, Y.; Behar, S.; Goldenberg, I.; Boyko, V.; Chouraqui, P. Usefulness of combining serum uric acid and C-reactive protein for risk stratification of patients with coronary artery disease (Bezafibrate Infarction Prevention [BIP] study). Am. J. Cardiol. 2009, 104, 194-198.
65. Nathanson, D.; Zethelius, B.; Berne, C.; Lind, L.; Andrén, B.; Ingelsson, E.; Holst, J.J.; Nyström, T. Plasma levels of glucagon like peptide-1 associate with diastolic function in elderly men. Diabet. Med. 2011, 28, 301-305.
66. Kojima, S.; Funahashi, T.; Otsuka, F.; Maruyoshi, H.; Yamashita, T.; Kajiwara, I.; Shimomura, H.; Miyao, Y.; Fujimoto, K.; Sugiyama, S. et al. Future adverse cardiac events can be predicted by persistently low plasma adiponectin concentrations in men and marked reductions of adiponectin in women after acute myocardial infarction. Atherosclerosis 2007, 194, 204-213.
67. Gao, R.; Zhang, J.; Cheng, L.; Wu, X.; Dong, W.; Yang, X.; Li, T.; Liu, X.; Xu, Y.; Li, X. et al. A phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure. J. Am. Coll. Cardiol. 2010, 55, 1907-1914.
68. Jabbour, A.; Hayward, C.S.; Keogh, A.M.; Kotlyar, E.; McCrohon, J.A.; England, J.F.; Amor, R.; Liu, X.; Li, X.Y.; Zhou, M.D. et al. Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses. Eur. J. Heart Fail. 2011, 13, 83-92.
69. Sokos, G.G.; Nikolaidis, L.A.; Mankad, S.; Elahi, D.; Shannon, R.P. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J. Card. Fail. 2006, 12, 694-699.
70. Read, P.A.; Hoole S.P.; White, P.A.; Khan, F.Z.; O'Sullivan, M.; West, N.E.; Dutka, D.P. A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans. Circ. Cardiovasc. Interv. 2011, 4, 266-272.
71. Read, P.A.; Khan, F.Z.; Dutka, D.P. Cardioprotection against ischemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease. Heart 2012, 98, 408-413.
72. Kondo, K.; Shibata, R.; Unno, K.; Shimano, M.; Ishii, M.; Kito, T.; Shintani, S.; Walsh, K.; Ouchi, N.; Murohara, T. Impact of a single intracoronary administration of adiponectin on myocardial ischemia/reperfusion injury in a pig model. Circ. Cardiovasc. Interv. 2010, 3, 166-173.